Get the Stockscreener App
1.46
3.28%
0.0464
After Hours:
1.59
0.13
+8.90%
Cocrystal Pharma Inc stock is traded at $1.46, with a volume of 33,952.
It is up +3.28% in the last 24 hours and down -7.59% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
See More
Previous Close:
$1.4136
Open:
$1.41
24h Volume:
33,952
Relative Volume:
1.55
Market Cap:
$13.33M
Revenue:
-
Net Income/Loss:
$-17.93M
P/E Ratio:
-0.8249
EPS:
-1.77
Net Cash Flow:
$-14.28M
1W Performance:
+11.45%
1M Performance:
-7.59%
6M Performance:
-25.13%
1Y Performance:
-6.16%
1-Day Range:
$1.36
$1.48
1-Week Range:
$1.2318
$1.48
52-Week Range:
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.46 | 13.33M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-988 | COCP Stock News - GuruFocus
Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times
First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan
Cocrystal Pharma Presents to Investment Community - TipRanks
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq
Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia
What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World
COCP: Norovirus Challenge Study Planned for 2025… - MSN
Cocrystal Pharma, Inc. SEC 10-K Report - TradingView
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan
Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight - openPR.com
Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR
Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire
New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
What is Northland Capmk’s Forecast for CECO FY2024 Earnings? - Defense World
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):